Novozymes, the leader in industrial enzymes, has also been leading in the sustainability of its enzyme products and their impacts. The company further explains and demonstrates in commitment to sustainability in this short video, well worth a few minutes of your time to watch:
Novozymes sustainability video
Codexis, Inc (Redwood City, CA), a world-leader in technology for engineering enzymes to improve performance, announced a technology collaboration and license agreement with pharmaceutical giant GlaxoSmithKline (GSK) today.
Under the terms of the agreement that were made public so far, Codexis will receive $25 million through a series of payments for technology transfer, plus additional milestone and royalty opportunities. These addition opportunities are not trivial; they range in value between $5.75 million and $38.5 million per project, according to the press release.
According to Codexis, this agreement marks the first time that Codexis has licensed its enzyme engineering platform technology called CodeEvolver to a company in the healthcare field. On the rationale behind the deal for GSK, we have this from John Baldoni, Senior Vice President, Platform Technology and Science of GSK: “Our goal is to manufacture small molecules more efficiently and sustainably and this platform will assist us to do that.”